How would you further evaluate and treat this patient? Heart failure with preserved ejection fraction is a heterogeneous syndrome. The diagnosis of the condition requires ruling out potential ...

Background Early heart failure (HF) diagnosis is crucial to ensure that optimal guideline-directed medical therapy (GDMT) is ...

The following is a summary of “Reduced antioxidant high-density lipoprotein function in heart failure with preserved ejection ...

Researchers discovered that ALPK2, a heart-specific enzyme, may protect against HFpEF by activating TPM1 in heart muscle ...

A recent study published in the Clinical Research in Cardiology journal linked impaired high-density lipoprotein (HDL) ...

Finerenone treatment vs placebo was associated with a reduced risk for new-onset diabetes by 24% among patients with HFmrEF or HFpEF.

A severe infection that requires hospitalization can put you at increased risk for future heart failure. People hospitalized ...

Bayer seeks European marketing approval for use of finerenone in adult patients with HF with a left ventricular ejection fraction (LVEF) of =40%: Berlin Tuesday, February 4, 2025, ...

What is ALPK2, and how can it help treat heart failure? Researchers have found that this heart-specific enzyme may prevent ...

on Thursday announced positive interim data from its ongoing Phase 1b clinical trial of TX45 in patients with Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction.

Researchers from the Nagoya University Graduate School of Medicine identified an enzyme, alpha-kinase 2 (ALPK2) that is ...

Bayer has filed its mineralocorticoid receptor antagonist (MRA) finerenone as a treatment for a common form of heart failure ...